Suppchains, the U.S. operating entity of Farmmi (FRM), has achieved a pivotal regulatory milestone by receiving approval from the U.S. Food and Drug Administration for its novel dietary supplement manufacturing facility. The clearance marks a critical step in Farmmi’s North American market strategy and paves the way for commercial distribution of its wellness products.
- Suppchains, Farmmi’s U.S. subsidiary, received FDA cGMP compliance approval for its NC manufacturing facility
- Facility has annual production capacity of 12 million units for dietary supplements
- Initial product focus includes plant-based protein powders and adaptogenic supplements
- Full U.S. market distribution rights granted post-approval, enabling nationwide sales
- Internal forecasts project U.S. revenue contribution to grow by up to 25% within one year
- FRM stock rose 6.8% in early trading following the announcement
Suppchains, a wholly owned subsidiary of Farmmi Inc. (FRM), has officially received FDA confirmation of compliance for its newly constructed dietary supplement manufacturing facility located in North Carolina. The approval, issued under the FDA’s Current Good Manufacturing Practice (cGMP) regulations, validates the facility’s adherence to stringent quality and safety standards for human consumption products. This milestone follows a 14-month review process and includes successful inspections of production lines, quality control systems, and documentation protocols. The facility is equipped to produce over 12 million units annually, with initial capacity focused on plant-based protein powders and adaptogenic supplements targeting the health and wellness segment. The regulatory green light strengthens Farmmi’s position in the U.S. consumer staples market, where demand for certified, transparently sourced supplements continues to grow. With the FDA’s clearance, Suppchains is now eligible to distribute products across all 50 states and initiate sales through e-commerce and major retail partners in early Q2 2026. The development is expected to support Farmmi’s broader operational expansion, potentially increasing U.S. revenue contributions by up to 25% within the next fiscal year, according to internal projections. Investors have responded positively, with FRM shares rising 6.8% in early trading following the announcement.